Vaccination in children with immune-mediated disorders

被引:1
|
作者
Marinho, Ana Karolina Barreto Berselli [1 ]
机构
[1] Univ Sao Paulo HCFMUSP, Hosp Clin, Fac Med, Serv Imunol Clin & Alergia, Sao Paulo, SP, Brazil
关键词
Children with immune-mediated rheumatic; inflamma-tory diseases; Live attenuated vaccines; Non-live" vaccines; Immunogenicity; Safety; JUVENILE IDIOPATHIC ARTHRITIS; PNEUMOCOCCAL CONJUGATE VACCINE; RHEUMATIC-DISEASES; PEDIATRIC-PATIENTS; VARICELLA VACCINE; IMMUNOGENICITY; SAFETY; TOLERABILITY; ADOLESCENTS; IMMUNIZATION;
D O I
10.1016/j.jped.2022.11.008
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: To present an updated review of recommendations for the vaccination of children with immune-mediated diseases, with an emphasis on rheumatic and inflammatory diseases.Source of data: Studies published in the PubMed and Scielo databases between 2002 and 2022, Guidelines of Brazilian Scientific Societies, Manuals and Technical Notes of the Ministry of Health of Brazil, on current immunization schedules for special populations. Data synthesis: Immunosuppressive drugs and biological agents reduce the immunogenicity of vaccines and favor susceptibility to infections. The safety and efficacy of immunogens are impor-tant points for vaccination in children with immune-mediated diseases. The safety threshold of a vaccine applied to immunocompromised individuals can be reduced when compared to healthy individuals. Very often, the recommendations for the immunization of children with immune -mediated diseases follow the recommendations for immunocompromised patients. Vaccination against COVID-19, on the other hand, should ideally occur when the disease is stabilized and in the absence of a low degree of immunosuppression. The patients should be informed about the possibility that the immunization may fail during treatment with immunosuppressants. Specific vaccination schedules should be considered to ensure better protection.Conclusions: Recent studies have allowed updating the recommendations on the safety and immu-nogenicity of vaccination in children with immune-mediated diseases, especially for live attenu-ated vaccines. There is a scarcity of data on the safety and efficacy of COVID-19 vaccines in patients, particularly pediatric patients, with rheumatic diseases. The completion of ongoing stud-ies is expected to help guide recommendations on COVID-19 vaccines in this group of patients.(c) 2022 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:S62 / S69
页数:8
相关论文
共 50 条
  • [21] Safety evaluation of adalimumab in immune-mediated inflammatory disorders: a rheumatoloairal point of view
    Duquenne, Laurence
    Gul, Hanna
    Emery, Paul
    EXPERT OPINION ON DRUG SAFETY, 2019, 18 (01) : 11 - 19
  • [22] Assessment of immune responses to hepatitis A vaccination in children aged 1 and 2 years
    Celebi, Solmaz
    Hacimustafaoglu, Mustafa Kemal
    Albayrak, Yucehan
    Sinirtas, Ayse Melda
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2013, 43 (04) : 617 - 624
  • [23] Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
    Abu-Sbeih, Hamzah
    Ali, Faisal S.
    Naqash, Abdul Rafeh
    Owen, Dwight H.
    Patel, Sandipkumar
    Otterson, Gregory A.
    Kendra, Kari
    Ricciuti, Biagio
    Chiari, Rita
    De Giglio, Andrea
    Sleiman, Joseph
    Funchain, Pauline
    Wills, Beatriz
    Zhang, Jiajia
    Naidoo, Jarushka
    Philpott, Jessica
    Gao, Jianjun
    Subudhi, Sumit K.
    Wang, Yinghong
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) : 2738 - +
  • [24] Vaccination and auto-immune rheumatic diseases: lessons learnt from the 2009 H1N1 influenza virus vaccination campaign
    Touma, Zahi
    Gladman, Dafna D.
    Urowitz, Murray B.
    CURRENT OPINION IN RHEUMATOLOGY, 2013, 25 (02) : 164 - 170
  • [25] Biologics - pathogenesis and characteristics of immune-mediated adverse events
    Hausmann, O.
    Manigold, T.
    ALLERGOLOGIE, 2013, 36 (10) : 452 - 459
  • [26] Vaccination coverage in children with rheumatic diseases
    Bizjak, M.
    Blazina, S.
    Avramovic, M. Zajc
    Markelj, G.
    Avcin, T.
    Toplak, N.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (01) : 164 - 170
  • [27] Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura
    Poullin, P.
    Bornet, C.
    Veyradier, A.
    Coppo, P.
    DRUGS OF TODAY, 2019, 55 (06) : 367 - 376
  • [28] Rituximab in the treatment of immune-mediated thrombotic thrombocytopenic purpura
    Ozpolat, Hasan Tahsin
    Stolla, Moritz
    BLOOD TRANSFUSION, 2023, 21 (05) : 369 - 374
  • [29] Immune-mediated respiratory adverse events of checkpoint inhibitors
    Tabchi, Samer
    Messier, Christine
    Blais, Normand
    CURRENT OPINION IN ONCOLOGY, 2016, 28 (04) : 269 - 277
  • [30] Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force
    Moreira Gomes Tavares, Anna Carolina Faria
    Guedes de Melo, Ana Karla
    Cruz, Vitor Alves
    de Souza, Viviane Angelina
    de Carvalho, Joana Starling
    Libardi Lira Machado, Ketty Lysie
    de Azevedo Valadares, Lilian David
    dos Reis Neto, Edgard Torres
    Vieira de Rezende, Rodrigo Poubel
    Brandao de Resende Guimaraes, Maria Fernanda
    Ferreira, Gilda Aparecida
    Braz, Alessandra de Sousa
    Rodrigues de Abreu Vieira, Rejane Maria
    Pinheiro, Marcelo de Medeiros
    Euzebio Ribeiro, Sandra Lucia
    Gomes Rios Bica, Blanca Elena
    Baptista, Katia Lino
    da Costa, Izaias Pereira
    Lopes Marques, Claudia Diniz
    Lemos Lopes, Maria Lucia
    Martinez, Jose Eduardo
    Neubarth Giorgi, Rina Dalva
    Henrique da Mota, Licia Maria
    Araujo da Rocha Loures, Marcos Antonio
    Paiva, Eduardo dos Santos
    Monticielo, Odirlei Andre
    Xavier, Ricardo Machado
    Kakehasi, Adriana Maria
    Salviato Pileggi, Gecilmara Cristina
    ADVANCES IN RHEUMATOLOGY, 2022, 62 (01)